203 related articles for article (PubMed ID: 36517664)
1. Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study.
Layton JB; Forns J; McQuay LJ; Danysh HE; Dempsey C; Anthony MS; Turner ME
Drug Saf; 2023 Feb; 46(2):195-208. PubMed ID: 36517664
[TBL] [Abstract][Full Text] [Related]
2. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ
Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829
[TBL] [Abstract][Full Text] [Related]
3. Falls and Fractures in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study.
Layton JB; Forns J; Turner ME; Dempsey C; Bartsch JL; Anthony MS; Danysh HE; Ritchey ME; Demos G
Drugs Real World Outcomes; 2022 Mar; 9(1):9-22. PubMed ID: 34718963
[TBL] [Abstract][Full Text] [Related]
4. Risk of long-term care admissions among Medicare beneficiaries treated with pimavanserin or quetiapine for Parkinson's disease psychosis in USA: a retrospective administrative claims database analysis.
Rajagopalan K; Rashid N; Doshi D
J Comp Eff Res; 2024 Jan; 13(1):e230114. PubMed ID: 38099518
[No Abstract] [Full Text] [Related]
5. Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics.
Rajagopalan K; Rashid N; Kumar S; Doshi D
J Med Econ; 2023; 26(1):34-42. PubMed ID: 36444507
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
[TBL] [Abstract][Full Text] [Related]
7. Patients treated with pimavanserin or quetiapine for Parkinson's disease psychosis: analysis of health resource utilization patterns among Medicare beneficiaries.
Rajagopalan K; Rashid N; Doshi D
J Med Econ; 2023; 26(1):769-776. PubMed ID: 37272069
[TBL] [Abstract][Full Text] [Related]
8. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
[No Abstract] [Full Text] [Related]
10. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Ballard C; Isaacson S; Mills R; Williams H; Corbett A; Coate B; Pahwa R; Rascol O; Burn DJ
J Am Med Dir Assoc; 2015 Oct; 16(10):898.e1-7. PubMed ID: 26239690
[TBL] [Abstract][Full Text] [Related]
11. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
[TBL] [Abstract][Full Text] [Related]
12. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
Yuan M; Sperry L; Malhado-Chang N; Duffy A; Wheelock V; Farias S; O'Connor K; Olichney J; Shahlaie K; Zhang L
Brain Behav; 2017 Jun; 7(6):e00639. PubMed ID: 28638698
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analyses evaluating the mortality risk associated with pimavanserin or other atypical antipsychotics in patients with Parkinson disease psychosis.
Isaacson SH; Pahwa R; Pagan F; Abler V; Truong D
Clin Park Relat Disord; 2024; 10():100256. PubMed ID: 38770047
[TBL] [Abstract][Full Text] [Related]
15. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
16. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
Isaacson SH; Citrome L
Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847
[TBL] [Abstract][Full Text] [Related]
17. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
[TBL] [Abstract][Full Text] [Related]
18. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
[TBL] [Abstract][Full Text] [Related]
19. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
20. Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
Sellers J; Darby RR; Farooque A; Claassen DO
Drugs Aging; 2019 Jul; 36(7):647-653. PubMed ID: 30924099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
